JP2012176953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012176953A5 JP2012176953A5 JP2012087648A JP2012087648A JP2012176953A5 JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5 JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- fragment
- kir2dl1
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 25
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 25
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims 17
- 102000047041 human KIR2DL1 Human genes 0.000 claims 13
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 5
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 claims 4
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims 4
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000058207 human KIR2DL2 Human genes 0.000 claims 3
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 claims 2
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 102000053035 human KIR2DS3 Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48389403P | 2003-07-02 | 2003-07-02 | |
| US60/483,894 | 2003-07-02 | ||
| US54547104P | 2004-02-19 | 2004-02-19 | |
| US60/545,471 | 2004-02-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Division JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Division JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012176953A JP2012176953A (ja) | 2012-09-13 |
| JP2012176953A5 true JP2012176953A5 (enExample) | 2013-04-18 |
| JP5826697B2 JP5826697B2 (ja) | 2015-12-02 |
Family
ID=33567703
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516606A Expired - Lifetime JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
| JP2006515738A Expired - Lifetime JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2012087648A Expired - Lifetime JP5826697B2 (ja) | 2003-07-02 | 2012-04-06 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2015042824A Expired - Lifetime JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516606A Expired - Lifetime JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
| JP2006515738A Expired - Lifetime JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Expired - Lifetime JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9902936B2 (enExample) |
| EP (3) | EP2289939B1 (enExample) |
| JP (5) | JP4871125B2 (enExample) |
| KR (5) | KR101420344B1 (enExample) |
| CN (2) | CN103467602B (enExample) |
| AT (1) | ATE490984T1 (enExample) |
| AU (2) | AU2004253770C1 (enExample) |
| BR (2) | BRPI0412138B8 (enExample) |
| CA (2) | CA2530272C (enExample) |
| CY (1) | CY1113394T1 (enExample) |
| DE (1) | DE602004030464D1 (enExample) |
| DK (2) | DK1673397T3 (enExample) |
| ES (2) | ES2393485T3 (enExample) |
| HR (1) | HRP20120845T1 (enExample) |
| IL (3) | IL172613A (enExample) |
| MX (1) | MXPA05013923A (enExample) |
| NO (4) | NO338818B1 (enExample) |
| PL (1) | PL1639013T3 (enExample) |
| PT (1) | PT1639013E (enExample) |
| RU (2) | RU2376315C2 (enExample) |
| WO (2) | WO2005003168A2 (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| US7803376B2 (en) | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| AU2005238300A1 (en) * | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for treating proliferative disorders such as NK-type LDGL |
| AU2005259221B2 (en) * | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| RU2410396C2 (ru) * | 2004-07-01 | 2011-01-27 | Ново Нордиск А/С | Антитела, связывающиеся с рецепторами kir2dl1,-2,-3 и не связывающиеся с рецептором kir2ds4, и их терапевтическое применение |
| ES2678094T3 (es) | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| EP1809738B1 (en) * | 2004-11-02 | 2014-03-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Compositions and methods for treating hyperproliferative disorders |
| EP3072522B1 (en) * | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| JP5295568B2 (ja) | 2005-01-06 | 2013-09-18 | ノヴォ ノルディスク アー／エス | Ｋｉｒ結合剤およびその使用方法 |
| US8551483B2 (en) | 2005-01-06 | 2013-10-08 | Innate Pharma S.A.S. | Methods of treating viral infections by administering KIR2DL-binding antibodies |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| EP2322557B1 (en) | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| AU2008204433B2 (en) * | 2007-01-11 | 2014-03-13 | Novo Nordisk A/S | Anti-KIR antibodies, formulations, and uses thereof |
| US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
| EP2376653A2 (en) * | 2008-12-29 | 2011-10-19 | Yissum Research Development Company of The Hebrew University of Jerusalem | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
| JP5766619B2 (ja) * | 2010-02-08 | 2015-08-19 | 株式会社日本バイオセラピー研究所 | Ｎｋ細胞強化型血液製剤の製造方法 |
| CA2818684C (en) | 2010-11-22 | 2023-02-21 | Innate Pharma Sa | Nk cell modulating treatments and methods for treatment of hematological malignancies |
| EP2714741B1 (en) * | 2011-05-25 | 2019-10-30 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory disorders |
| WO2012175613A1 (en) | 2011-06-21 | 2012-12-27 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| MX2014005479A (es) * | 2011-11-23 | 2014-08-18 | Hoffmann La Roche | Celulas de mamifero que expresan cd40l y su uso. |
| EP2897980B1 (en) * | 2012-09-19 | 2019-11-06 | Innate Pharma | Kir3dl2 binding agents |
| US20150290316A1 (en) | 2012-10-02 | 2015-10-15 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| ES2707057T3 (es) | 2013-11-06 | 2019-04-02 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple |
| JP6654781B2 (ja) * | 2014-08-29 | 2020-02-26 | 国立大学法人北海道大学 | Ｋｉｒ２ｄｓ１に対するモノクローナル抗体 |
| US11639384B2 (en) | 2014-10-28 | 2023-05-02 | University Children's Hospital Tübingen | Treatment of pediatric BCP-ALL patients with an anti-KIR antibody |
| SG10201913124RA (en) | 2015-02-06 | 2020-03-30 | Nat Univ Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| SG10201912035YA (en) | 2015-04-17 | 2020-02-27 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| ES2905525T3 (es) | 2015-05-06 | 2022-04-11 | Snipr Tech Ltd | Alteración de poblaciones microbianas y modificación de la microbiota |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| BR112018000903A2 (pt) | 2015-07-16 | 2018-09-11 | Biokine Therapeutics Ltd. | composições e métodos para o tratamento de câncer |
| DK3370768T3 (da) | 2015-11-03 | 2022-03-21 | Janssen Biotech Inc | Antistoffer som specifikt binder pd-1 og anvendelser deraf |
| JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN109890387B (zh) | 2016-05-20 | 2022-06-14 | 拜尔哈文制药股份有限公司 | 谷氨酸调节剂与免疫疗法用以治疗癌症的用途 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| EP3484516A4 (en) | 2016-07-14 | 2020-03-18 | Fred Hutchinson Cancer Research Center | MULTIPLE CONSTRUCTIONS OF BI-SPECIFIC LINK AREAS HAVING A DIFFERENT EPITOPE LINK TO TREAT CANCER |
| AU2017335732B2 (en) | 2016-09-27 | 2024-11-21 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| KR102661905B1 (ko) | 2016-10-12 | 2024-04-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Tusc2 면역요법을 위한 방법 및 조성물 |
| KR20190068602A (ko) | 2016-10-21 | 2019-06-18 | 이나뜨 파르마 | 항-kir3dl2 작용제에 의한 치료 |
| AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| SG10202110594UA (en) | 2017-03-31 | 2021-11-29 | Bristol Myers Squibb Co | Methods of treating tumor |
| IL269801B2 (en) | 2017-04-05 | 2024-02-01 | Korea Res Inst Bioscience & Biotechnology | A fusion protein that activates NK cells, an NK cell, and a pharmaceutical preparation that includes them |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| WO2018218207A1 (en) | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| CN107261304A (zh) * | 2017-06-05 | 2017-10-20 | 中国兽医药品监察所 | 一种奶牛的布鲁氏菌病免疫试剂盒及其应用 |
| SG11202000402PA (en) | 2017-08-10 | 2020-02-27 | Nat Univ Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| CN108060137B (zh) * | 2017-12-26 | 2021-07-02 | 博生吉医药科技(苏州)有限公司 | Il7和il21修饰的nk92细胞、制备方法及其应用 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP2021512914A (ja) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法 |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| SG11202007945UA (en) | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| US12454561B2 (en) | 2018-03-19 | 2025-10-28 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| BR112020019418A2 (pt) | 2018-03-25 | 2021-02-17 | Snipr Biome Aps. | tratamento e prevenção de infecções microbianas |
| CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| WO2019226945A1 (en) | 2018-05-23 | 2019-11-28 | National University Of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3849565A4 (en) | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL297931B2 (en) | 2018-09-25 | 2025-03-01 | Harpoon Therapeutics Inc | DLL3 binding proteins and methods of use |
| KR20210109564A (ko) | 2018-12-21 | 2021-09-06 | 옹쎄오 | 신규의 컨쥬게이티드 핵산 분자 및 이의 용도 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CN111424012A (zh) * | 2020-03-30 | 2020-07-17 | 威海市中心医院 | 一种nk细胞培养用的饲养细胞去增殖能力的处理方法 |
| BR112022021884A2 (pt) | 2020-05-06 | 2022-12-20 | Dragonfly Therapeutics Inc | Proteínas que se ligam a nkg2d, cd16 e clec12a |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| US20240000837A1 (en) * | 2020-12-23 | 2024-01-04 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| PL4267105T3 (pl) | 2020-12-28 | 2025-06-30 | Bristol-Myers Squibb Company | Kompozycje przeciwciał i metody ich stosowania |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| CN118055840A (zh) | 2021-10-08 | 2024-05-17 | 3M创新有限公司 | 具有调节的刚度、减小的拉延区和力预算的狭缝模组件 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| WO2023111203A1 (en) | 2021-12-16 | 2023-06-22 | Onxeo | New conjugated nucleic acid molecules and their uses |
| CN118871451A (zh) | 2022-03-18 | 2024-10-29 | 百时美施贵宝公司 | 分离多肽的方法 |
| CN119562830A (zh) | 2022-06-02 | 2025-03-04 | 百时美施贵宝公司 | 抗体组合物及其使用方法 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024026385A1 (en) * | 2022-07-28 | 2024-02-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies |
| CN119654346A (zh) * | 2022-10-25 | 2025-03-18 | 第一三共株式会社 | 使用针对抑制型kir的激动剂逃避免疫排斥的方法 |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN117883553B (zh) * | 2024-01-12 | 2024-08-27 | 成都医学院 | Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
| IL108501A (en) * | 1994-01-31 | 1998-10-30 | Mor Research Applic Ltd | Antibodies and pharmaceutical compositions containing them |
| US5583034A (en) | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
| US5808028A (en) | 1994-05-24 | 1998-09-15 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clone of a P58 receptor protein and uses thereof |
| NZ298145A (en) | 1994-12-29 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament |
| US6750044B1 (en) | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
| DE59913716D1 (de) | 1998-10-29 | 2006-09-07 | Dakocytomation Denmark As | Nachweis von säure-resistenten mikroorganismen im stuhl |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| US7803376B2 (en) * | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| PT2476705E (pt) | 2004-12-28 | 2016-02-09 | Innate Pharma | Anticorpos monoclonais contra nkg2a |
| JP5295568B2 (ja) | 2005-01-06 | 2013-09-18 | ノヴォ ノルディスク アー／エス | Ｋｉｒ結合剤およびその使用方法 |
| US8551483B2 (en) * | 2005-01-06 | 2013-10-08 | Innate Pharma S.A.S. | Methods of treating viral infections by administering KIR2DL-binding antibodies |
| EP3072522B1 (en) * | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| EP2322557B1 (en) | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| AU2008204433B2 (en) | 2007-01-11 | 2014-03-13 | Novo Nordisk A/S | Anti-KIR antibodies, formulations, and uses thereof |
| EP2714741B1 (en) * | 2011-05-25 | 2019-10-30 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory disorders |
| HK1213924A1 (zh) * | 2012-10-23 | 2016-07-15 | Bristol-Myers Squibb Company | 用於治療癌症的抗kir和抗ctla-4抗體組合 |
| ES2707057T3 (es) * | 2013-11-06 | 2019-04-02 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple |
| US9884593B2 (en) * | 2015-02-12 | 2018-02-06 | Pro-Gard Products, Llc | Weapon mounting system |
-
2004
- 2004-07-01 WO PCT/DK2004/000470 patent/WO2005003168A2/en not_active Ceased
- 2004-07-01 RU RU2005140152/13A patent/RU2376315C2/ru active
- 2004-07-01 ES ES04744115T patent/ES2393485T3/es not_active Expired - Lifetime
- 2004-07-01 AT AT04738967T patent/ATE490984T1/de not_active IP Right Cessation
- 2004-07-01 KR KR1020127013323A patent/KR101420344B1/ko not_active Expired - Lifetime
- 2004-07-01 PL PL04744115T patent/PL1639013T3/pl unknown
- 2004-07-01 CN CN201310392765.XA patent/CN103467602B/zh not_active Expired - Lifetime
- 2004-07-01 EP EP10178580.6A patent/EP2289939B1/en not_active Expired - Lifetime
- 2004-07-01 WO PCT/IB2004/002464 patent/WO2005003172A2/en not_active Ceased
- 2004-07-01 BR BRPI0412138A patent/BRPI0412138B8/pt not_active IP Right Cessation
- 2004-07-01 DE DE602004030464T patent/DE602004030464D1/de not_active Expired - Lifetime
- 2004-07-01 AU AU2004253770A patent/AU2004253770C1/en not_active Expired
- 2004-07-01 CA CA2530272A patent/CA2530272C/en not_active Expired - Lifetime
- 2004-07-01 PT PT47441159T patent/PT1639013E/pt unknown
- 2004-07-01 EP EP04744115A patent/EP1639013B1/en not_active Expired - Lifetime
- 2004-07-01 KR KR1020127002275A patent/KR101325023B1/ko not_active Expired - Lifetime
- 2004-07-01 DK DK04738967.1T patent/DK1673397T3/da active
- 2004-07-01 MX MXPA05013923A patent/MXPA05013923A/es active IP Right Grant
- 2004-07-01 KR KR1020137013482A patent/KR101444717B1/ko not_active Expired - Lifetime
- 2004-07-01 JP JP2006516606A patent/JP4871125B2/ja not_active Expired - Lifetime
- 2004-07-01 ES ES10178580T patent/ES2725526T3/es not_active Expired - Lifetime
- 2004-07-01 DK DK04744115.9T patent/DK1639013T3/da active
- 2004-07-01 KR KR1020067000025A patent/KR20060079180A/ko not_active Ceased
- 2004-07-01 CA CA002530591A patent/CA2530591A1/en not_active Abandoned
- 2004-07-01 CN CN201310057089.0A patent/CN103588880B/zh not_active Expired - Lifetime
- 2004-07-01 US US10/563,045 patent/US9902936B2/en active Active
- 2004-07-01 HR HRP20120845TT patent/HRP20120845T1/hr unknown
- 2004-07-01 RU RU2006102960/10A patent/RU2404993C2/ru active
- 2004-07-01 KR KR1020067000109A patent/KR101375153B1/ko not_active Expired - Lifetime
- 2004-07-01 BR BRPI0412153A patent/BRPI0412153B8/pt not_active IP Right Cessation
- 2004-07-01 JP JP2006515738A patent/JP5015592B2/ja not_active Expired - Lifetime
- 2004-07-01 AU AU2004253630A patent/AU2004253630B2/en not_active Expired
- 2004-07-01 EP EP04738967A patent/EP1673397B1/en not_active Expired - Lifetime
-
2005
- 2005-12-15 IL IL172613A patent/IL172613A/en active IP Right Grant
- 2005-12-19 NO NO20056048A patent/NO338818B1/no unknown
- 2005-12-20 IL IL172700A patent/IL172700A/en active IP Right Grant
-
2006
- 2006-02-01 NO NO20060528A patent/NO338255B1/no unknown
-
2012
- 2012-04-06 JP JP2012087648A patent/JP5826697B2/ja not_active Expired - Lifetime
- 2012-11-28 CY CY20121101151T patent/CY1113394T1/el unknown
-
2015
- 2015-03-04 JP JP2015042824A patent/JP6556465B2/ja not_active Expired - Lifetime
- 2015-04-28 IL IL238490A patent/IL238490A0/en unknown
-
2016
- 2016-02-16 NO NO20160264A patent/NO342318B1/no unknown
- 2016-03-10 NO NO20160411A patent/NO343342B1/no unknown
-
2018
- 2018-01-22 US US15/876,839 patent/US11365393B2/en active Active
- 2018-04-16 JP JP2018078329A patent/JP2018153185A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012176953A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
| JP2017048240A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2018516853A5 (enExample) | ||
| JP2018510636A5 (enExample) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2017114866A5 (enExample) | ||
| CN110291109A (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| JP2009225799A5 (enExample) | ||
| HRP20230411T1 (hr) | Dvostruko ciljanje | |
| JP2019535670A5 (enExample) | ||
| JP2012502649A5 (enExample) | ||
| JP2012116856A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2013506428A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2018520667A5 (enExample) | ||
| MY188237A (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2015504421A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 |